Remepy develops Hybrid Drugs that combine pharmaceutical molecules with AI-driven digital protocols to improve clinical outcomes. These therapies integrate traditional medication with app-delivered digital interventions targeting motor, cognitive, and mental functions. The company leverages a Drug-SaMD combination pathway to validate and approve these novel, personalized treatment modalities.
Funding
$12.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neuro-immune conditions often require a combination of drugs and non-pharmacological interventions, which are difficult to standardize and personalize for each patient. Coordinating these interventions and adapting them based on patient progress presents a significant challenge.
Solution
Remepy is developing hybrid drugs that combine traditional pharmaceuticals with digital interventions delivered through a therapeutic app, creating a Software as a Medical Device (SaMD) drug combination. The app provides patients with personalized cognitive, psychological, motor, and behavioral interventions designed to work synergistically with the drug's mechanism of action. By integrating these digital molecules, Remepy aims to enhance brain connectivity, modulate immune biomarkers, and improve overall treatment outcomes. The app also monitors patient feedback, activity, and progress, allowing for real-time adaptation of the treatment protocol.
Target Audience
Remepy's primary target audience includes patients with neuro-immune conditions, as well as physicians and drug developers seeking to enhance treatment outcomes through personalized, data-driven combination therapies.
Features
- Therapeutic app delivering personalized cognitive, psychological, motor, and behavioral interventions
- Interventions based on principles of multi-sensory integration, sensory masking, and sensory substitution
- Digital treatment protocols with daily interventions, tailored to the specific drug treatment
- Real-time adaptation of treatment based on patient feedback, activity, and progress
- fMRI imaging validated connectivity improvements in brain areas related to memory, spatial navigation, motor control, and emotional control
- Demonstrated reduction in IL-17, IL-18, IL-23 and TNF-α levels in clinical studies